Controversies in Indolent Lymphoma

**Session Title:** Controversies in Indolent Lymphoma  
**Session Type:** Education Session  
**Time:** 1:00 PM - 2:15 PM  
**Location:** E354a

- What Is the Best First-Line Treatment Strategy for Indolent Lymphomas?  
  *Gilles A. Salles, MD, PhD*
- What Is the Role of Transplantation for Indolent Lymphoma?  
  *Ajay K. Gopal, MD*
- What Is the Best Strategy for Integrating New Agents into Current Treatment of Follicular Lymphoma?  
  *Sonali M. Smith, MD (Chair)*

The Cost of Lung Cancer Care: Screening, Personalized Medicine, and Palliative Care

**Session Title:** The Cost of Lung Cancer Care: Screening, Personalized Medicine, and Palliative Care  
**Session Type:** Education Session  
**Time:** 1:00 PM - 2:15 PM  
**Location:** E Hall D1

- The Cost of Lung Cancer Screening  
  *Bernardo Haddock Lobo Goulart, MD*
- Moving toward Personalized Medicine in Non-small Cell Lung Cancer: The Cost of Targeting Therapy, Including Diagnostics, Patient Selection, and Targeted Therapies  
  *Natasha B. Leighl, MD, FRCPC (Chair)*
- The Cost of Palliative Therapy: Discuss Current Trends in the Costs of Palliative Therapy including Systemic Therapy, Early Initiation of Supportive Care, and the Costs of Futile Therapy  
  *Craig Earle, MD*

Uterine Sarcoma: Challenging Cases for the Interdisciplinary Team

**Session Title:** Uterine Sarcoma: Challenging Cases for the Interdisciplinary Team  
**Session Type:** Education Session  
**Time:** 1:00 PM - 2:15 PM  
**Location:** E Arie Crown Theater

- An Overview of Uterine Sarcomas: Histology and Its Implications on Therapy  
  *Martee Leigh Hensley, MD, MSc (Chair)*
- Radiotherapy Techniques for Uterine Sarcoma  
  *Anuja Jhingran, MD*
- Metastatic Sarcoma of the Uterus: Indications for Surgical Therapy  
  *John Patrick Curtin, MD*

BRCA Testing and PARP Inhibitors in the Treatment of Breast Cancer - Ticketed Session

**Session Title:** BRCA Testing and PARP Inhibitors in the Treatment of Breast Cancer - Ticketed Session  
**Session Type:** Meet the Professor Session  
**Time:** 1:00 PM - 2:15 PM  
**Location:** E451a

- PARP Inhibitor Therapy in Genetically Tested BRCA Patients  
  *Mark E. Robson, MD*

Cancer Prevention for Cancer Survivors

**Session Title:** Cancer Prevention for Cancer Survivors  
**Session Type:** Extended Education Session  
**Time:** 1:00 PM - 3:15 PM  
**Location:** E353

- Cancer Prevention in Cancer Survivors: Defining the Problem  
  *Lois B. Travis, MD, ScD (Chair)*
• Genetic Factors Contributing to Risk of Second Cancers to Include Germ-Line Predisposition and Novel Biomarkers of Risk
  
  James M. Allan, DPhil

• Antineoplastic Treatment-Related Second Cancers (Chemotherapy, Biologics, Growth Factors, Hormones)
  
  Mark Norman Levine, MD

• Contribution of Radiation to Risk of Second Cancers in Cancer Survivors
  
  Andrea K. Ng, MD, MPH

• The Impact of Behavioral, Environmental, and Other Shared Risk Factors (Including Age, Smoking, and Obesity) That Contribute to Second Cancers
  
  Wendy Demark-Wahnefried, PhD, RD

• Surveillance and Management Strategies for Cancer Survivors
  
  Marie Wood, MD

Session Title: From Discovery to Standards of Care in Clinical Trials of Head and Neck Cancer

Session Type: Extended Education Session

Time: 1:00 PM - 3:15 PM

Location: E354b

• Genetic Information
  
  David Sidransky, MD

• Integrated Molecular Approaches in Radiation Therapy
  
  Quynh-Thu Le, MD

• Molecular and Immunologic Approaches for Surgical Care
  
  Robert L. Ferris, MD, PhD

• Targeted Therapy for Head and Neck Cancer
  
  Ezra E. W. Cohen, MD (Chair)

• New Insights into Supportive Care of the Patient with Head and Neck Cancer
  
  Jill Gilbert, MD

Session Title: On the Shoulders of Giants: Historical Perspectives on Melanoma--Immunotherapy and Molecular Targeted Therapy

Session Type: Extended Education Session

Time: 1:00 PM - 3:15 PM

Location: S406

• Moderator
  
  Albert C. Lockhart, MD (Chair)

• Historical Perspectives of Immunotherapy of Melanoma
  
  Jeffrey Alan Sosman, MD

• Melanoma Molecular-Targeted Therapy
  
  Paul B. Chapman, MD

• Case Study Presenter
  
  Christine Marie Lovly, MD, PhD

• Case Study Presenter
  
  Marjorie Glass Zauderer, MD, MS

Session Title: Maintenance of Certification and Lifelong Learning Workshop - Ticketed Session

Session Type: Extended Education Session

Time: 1:00 PM - 4:00 PM

Location: E451b

• ABIM 2011 Update in Medical Oncology
  
  Nina J. Karlin, MD (Chair)
Session Title: Central Nervous System Tumors
Session Type: Poster Discussion Session
Display Time: 1:00 PM - 5:00 PM
Display Location: S102
Discussion Time: 4:30 PM - 5:30 PM
Discussion Location: S100a

- Co-Chair
  Christina Tsien, MD
- Co-Chair
  Mark R. Gilbert, MD

Brd. 1
- Phase I safety and pharmacokinetic (PK) study of veliparib in combination with whole brain radiation therapy (WBRT) in patients (pts) with brain metastases. (Abstract #2013)
  Minesh P. Mehta

Brd. 2
- FIP200 and Rb1 expression in CNS metastasis from breast cancer (CNS met): Potential predictors of patient outcome. (Abstract #2014)
  Nooshin Hashemi Sadraei

Brd. 3
- Intraventricular (IVe) topotecan for women with neoplastic meningitis (NM) associated with "responsive" malignancies. (Abstract #2015)
  Kurt A. Jaeckle

Brd. 4
- Addition of upfront whole-brain radiotherapy to surgery or stereotactic radiosurgery versus surgery or stereotactic radiosurgery alone for treatment of brain metastases: A systematic review and meta-analysis. (Abstract #2016)
  Yu Yang Soon

Brd. 5
- Modeling radiation dose to circulating lymphocytes during brain tumor treatment: Effects of target volume, dose rate, and treatment technique. (Abstract #2017)
  Susannah G. Yovino

Brd. 6
- Phase II trial of sunitinib as adjuvant therapy after stereotactic radiosurgery (SRS) in patients with 1-3 newly diagnosed brain metastases. (Abstract #2018)
  David M. Peereboom

- Discussion
  Paul D. Brown, MD

Brd. 7
- IDH1 status and survival benefit from surgical resection of enhancing and nonenhancing tumor in malignant astrocytomas. (Abstract #2019)
  Daniel P. Cahill

Brd. 8
- Genomic characterization of meningiomas. (Abstract #2020)
  Priscilla Kaliopi Brastianos
• MET and ALK in glioblastoma multiforme (GBM): Comparison of IHC and FISH. (Abstract #2021)
  
  *Kimary Kulig*

Brd. 10
• Pilocytic astrocytomas in adults: A retrospective study of 125 patients. (Abstract #2022)
  
  *Brett James Theeler*

Brd. 11
• Recurrent genetic alterations in primary central nervous system lymphoma of immunocompetent patients. (Abstract #2023)
  
  *Alberto Gonzalez*

Brd. 12
• Blood alterations preceding clinical manifestation of glioblastoma. (Abstract #2024)
  
  *Aysegul Ilhan-Mutlu*

• Discussion
  
  *Elizabeth A. Maher, MD, PhD*

Brd. 13
• Impact of adjuvant anti-VEGF therapy on treatment-related pseudoprogression in patients with newly diagnosed glioblastoma receiving chemoradiation with or without anti-VEGF therapy. (Abstract #2025)
  
  *Marco C Pinho*

Brd. 14
• A single-institution phase II trial of radiation (RT), temozolomide (TMZ), erlotinib, and bevacizumab for initial treatment of glioblastoma (GBM). (Abstract #2026)
  
  *Jennifer Leigh Clarke*

Brd. 15
• Vorinostat, temozolomide, and bevacizumab for patients with recurrent glioblastoma: A phase I/II trial. (Abstract #2027)
  
  *Katherine B. Peters*

Brd. 16
• Bevacizumab for recurrent WHO grade III anaplastic glioma (AG). (Abstract #2028)
  
  *Anna Maria Delios*

Brd. 17
• Bevacizumab versus bevacizumab plus vorinostat in adults with recurrent malignant glioma: Results of a phase I part of a phase I/II trial. (Abstract #2029^)
  
  *Jing Wu*

Brd. 18
• Differences in outcome due to bevacizumab (BEV) discontinuation versus BEV failure in adults with glioblastoma. (Abstract #2030)
  
  *Mark Daniel Anderson*

• Discussion
  
  *John Frederick De Groot, MD*

Brd. 19
• NCCTG N057K phase II trial of everolimus, temozolomide, and radiotherapy in patients with newly diagnosed glioblastoma: A North Central Cancer Treatment Group trial. (Abstract #2031)
  
  *Daniel Ma*
• Phase I/randomized phase II trial of either dasatinib or placebo combined with standard chemoradiotherapy for newly diagnosed glioblastoma multiforme (GBM): Final results of phase I study. (Abstract #2032)
  Nadia N. Laack

• Final results of a randomized phase III trial of nimotuzumab for the treatment of newly diagnosed glioblastoma in addition to standard radiation and chemotherapy with temozolomide versus standard radiation and temozolomide. (Abstract #2033)
  Manfred Westphal

• APG101_CD_002: A phase II, randomized, open-label, multicenter study of weekly APG101 plus reirradiation versus reirradiation in the treatment of patients with recurrent glioblastoma. (Abstract #2034)
  Martin Bendszus

• A phase II trial evaluating tumor penetration of bortezomib in patients with recurrent malignant gliomas treated prior to surgery and then treated with bortezomib and temozolomide postoperatively. (Abstract #2035)
  Jeffrey J. Raizer

• Lenalidomide and irinotecan in adults with recurrent malignant gliomas: Phase I results of the phase I/II trial. (Abstract #2036)
  Vinay K. Puduvalli

• Phase II trial of dose-dense temozolomide as initial treatment for progressive low-grade oligodendrogial tumors: A multicentric study of the Italian Association of Neuro-Oncology (AINO). (Abstract #2037)
  Roberta Ruda

• Discussion
  Jaishri O'Neill Blakeley, MD

---

Session Title: Gastrointestinal (Colorectal) Cancer
Session Type: Poster Discussion Session
Display Time: 1:00 PM - 5:00 PM
Display Location: E450b
Discussion Time: 4:30 PM - 5:30 PM
Discussion Location: E Arie Crown Theater

• Co-Chair
  Tony R. Reid, MD, PhD

• Co-Chair
  Weijing Sun, MD

• Validation of two gene-expression risk scores in a large colon cancer cohort and contribution to an improved prognostic method. (Abstract #3509)
  Arnaud Roth

• Validation of a genomic classifier (ColoPrint) for predicting outcome in the T3-MSS subgroup of stage II colon cancer patients. (Abstract #3510)
  Ramon Salazar
• Identification and validation of gene expression subtypes in a large set of colorectal cancer samples. (Abstract #3511)
  
  Eva Budinska

• Validation of the 12-gene colon cancer recurrence score (RS) in NSABP C07 as a predictor of recurrence in stage II and III colon cancer patients treated with 5FU/LV (FU) and 5FU/LV+oxaliplatin (FU+Ox). (Abstract #3512)
  
  Michael O'Connell

• The prognostic importance of miRNA-21 in stage II colon cancer: A population-based study. (Abstract #3513)
  
  Sanne Kjaer-Frifeldt

• Prognostic impact of BRAF and KRAS mutations and their relationship to DNA mismatch repair (MMR) status in 2,686 stage III colon cancer patients (pts) treated in a phase III study of adjuvant FOLFOX with or without cetuximab: NCCTG N0147. (Abstract #3514)
  
  Frank A. Sinicrope

• Discussion
  
  Richard L. Schilsky, MD

• BRAF, PIK3CA, and PTEN status and benefit from cetuximab (CET) in the treatment of advanced colorectal cancer (CRC): Results from NCIC CTG/AGITG CO.17. (Abstract #3515)
  
  Derek J. Jonker

• Epiregulin (EREG) and amphiregulin (AREG) gene expression to predict response to cetuximab therapy in combination with oxaliplatin (Ox) and 5FU in first-line treatment of advanced colorectal cancer (aCRC). (Abstract #3516)
  
  Richard A. Adams

• A novel interaction of genotype, gender, and adjuvant treatment in survival after resection of stage III colon cancer: Results of CALGB 89803. (Abstract #3517)
  
  Robert S. Warren

• Prospective evaluation of candidate SNPs of VEGF/VEGFR pathway in metastatic colorectal cancer (mCRC) patients (pts) treated with first-line FOLFIRI plus bevacizumab (BV). (Abstract #3518)
  
  Chiara Cremolini

• Ligand expression of the EGFR ligands amphiregulin, epieregulin, and amplification of the EGFR gene to predict for treatment efficacy in KRAS wild-type mCRC patients treated with cetuximab plus CAPIRI and CAPOX: Analysis of the randomized AIO CRC-0104 trial. (Abstract #3519^)
  
  Sebastian Stintzing

• Effect of low-frequency KRAS mutations on the response to anti-EGFR therapy in metastatic colorectal cancer. (Abstract #3520)
  
  David Tougeron
• MicroRNA signature to predict sensitivity to anti-EGFR monoclonal antibodies in metastatic colorectal cancer (mCRC). (Abstract #3521)
  
  Federico Cappuzzo

• Discussion
  
  Josep Tabernero, MD

Brd. 14

• Impact of age and medical comorbidity (MC) on adjuvant treatment outcomes for stage III colon cancer (CC): A pooled analysis of individual patient data from four randomized controlled trials. (Abstract #3522)
  
  Daniel G. Haller

Brd. 15

• Effect of oxaliplatin-based adjuvant therapy on post-relapse survival (PRS) in patients with stage III colon cancer: A pooled analysis of individual patient data from four randomized controlled trials. (Abstract #3523)
  
  Christopher Twelves

Brd. 16

• Randomized phase III study of adjuvant chemotherapy with oral uracil and tegafur plus leucovorin versus intravenous fluorouracil and levofolinate in patients (pts) with stage III colon cancer (CC): Final results of Japan Clinical Oncology Group study (JCOG0205). (Abstract #3524)
  
  Yasuhiro Shimada

Brd. 17

• Comparative evaluation of capecitabine or infusional leucovorin/5-fluorouracil (LV/5-FU) with or without oxaliplatin (Ox) for stage III colon cancer (CC): A pooled analysis of individual patient data from four randomized controlled trials. (Abstract #3525)
  
  Weijing Sun

Brd. 18

• Smoking status and prognosis in patients with stage III colon cancer: A correlative analysis of NCCTG phase III trial N0147. (Abstract #3526)
  
  Amanda I. Phipps

Brd. 19

• Adjuvant chemotherapy (AC) use and outcomes in stage II colon cancer (CC) with and without poor prognostic features. (Abstract #3527)
  
  Aalok Kumar

• Discussion
  
  Sharlene Gill, MD, MPH

Brd. 20

• BRAF V600 mutant colorectal cancer (CRC) expansion cohort from the phase I/II clinical trial of BRAF inhibitor dabrafenib (GSK2118436) plus MEK inhibitor trametinib (GSK1120212). (Abstract #3528)
  
  Ryan Bruce Corcoran

Brd. 21

• Pharmacodynamic biomarker-driven trial of MK-2206, an AKT inhibitor, with AZD6244 (selumetinib), a MEK inhibitor, in patients with advanced colorectal carcinoma (CRC). (Abstract #3529)
  
  Giovanna Speranza
• Overall survival (OS) of advanced colorectal cancer (aCRC) patients (pts) treated with the multipeptide vaccine IMA910: Results of a matched-pair analysis with arm C pts from COIN. (Abstract #3530)
  Tim Maughan

Brd. 23
• Molecular analysis of the randomized phase II/III study of the anti-IGF-1R antibody dalotuzumab (MK-0646) in combination with cetuximab (Cx) and irinotecan (Ir) in the treatment of chemorefractory KRAS wild-type metastatic colorectal cancer (mCRC). (Abstract #3531)
  David J. Watkins

Brd. 24
• Randomized phase II open-label study of mFOLFOX6 in combination with linifanib or bevacizumab for metastatic colorectal cancer. (Abstract #3532)
  Bert H. O’Neil

Brd. 25
• Use of next-generation sequencing (NGS) to detect a novel ALK fusion and a high frequency of other actionable alterations in colorectal cancer (CRC). (Abstract #3533)
  Jeffrey S. Ross

• Discussion
  George A. Fisher, MD, PhD

Session Title: Gynecologic Cancer
Session Type: Poster Discussion Session
Display Time: 1:00 PM - 5:00 PM
Display Location: E450a
Discussion Time: 4:30 PM - 5:30 PM
Discussion Location: E354a

• Co-Chair
  Carol Aghajanian, MD
• Co-Chair
  Gini F. Fleming, MD

Brd. 1
• A phase II, open-label, multicenter study of IMC-1121B (ramucirumab; RAM) monotherapy in the treatment of persistent or recurrent epithelial ovarian (EOC), fallopian tube (FTC), or primary peritoneal (PPC) carcinoma (CP12-0711/NCT00721162). (Abstract #5012)
  Richard T. Penson

Brd. 2
• Phase II trial of bevacizumab and pemetrexed for recurrent or persistent epithelial ovarian, fallopian tube, or primary peritoneal cancer. (Abstract #5013)
  Andrea R. Hagemann

Brd. 3
• Phase I trial of metronomic oral topotecan in combination with pazopanib utilizing a daily dosing schedule to treat recurrent or persistent gynecologic tumors. (Abstract #5014)
  Todd D. Tillmanns

Brd. 4
• Randomized phase II study of docetaxel plus vandetanib (D+V) versus docetaxel followed by vandetanib (D-V) in patients with persistent or recurrent epithelial ovarian, fallopian tube, or primary peritoneal carcinoma (OC): SWOG S0904. (Abstract #5015)
  Robert L. Coleman
• Phase II trial of irinotecan plus bevacizumab for heavily pretreated recurrent ovarian cancer. (Abstract #5016)
  
  *Salvia Sanjay Jain*

• Safety of front-line bevacizumab (BEV) combined with weekly paclitaxel (wPAC) and q3w carboplatin (C) for ovarian cancer (OC): Results from OCTAVIA. (Abstract #5017)
  
  *Antonio Gonzalez-Martin*

• Lenalidomide (REV) in asymptomatic late recurrent ovarian cancer (ROC) patients with increasing CA 125: A GINECO phase II trial. (Abstract #5018)
  
  *Frédéric Selle*

• Discussion
  
  *Gottfried E. Konecny, MD*

• A phase II study of RO4929097 (RO), a gamma-secretase inhibitor, in advanced platinum (Pt)-resistant (R) ovarian cancer (OC): A study of the PMH, Chicago, and California phase II consortia. (Abstract #5019)
  
  *Ivan Diaz-Padilla*

• Randomized trial of oral cyclophosphamide (C) with or without veliparib (V), an oral poly(ADP-ribose) polymerase (PARP) inhibitor, in patients with recurrent BRCA-positive ovarian, or primary peritoneal or high-grade serous ovarian carcinoma. (Abstract #5020)
  
  *Shivaani Kummar*

• Phase I/II study of weekly paclitaxel with or without MLN8237 (alisertib), an investigational aurora A kinase inhibitor, in patients with recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer (OC), or breast cancer (BrC): Phase I results. (Abstract #5021)
  
  *Gerald Steven Falchook*

• Use of chemotherapy (CT) in BRCA1/2 deficient ovarian cancer (BDOC) patients (pts) with poly-ADP-ribose polymerase inhibitor (PARPi) resistance: A multi-institutional study. (Abstract #5022)
  
  *Joo Ern Ang*

• A novel autologous oxidized whole-tumor antigen vaccine therapy for recurrent ovarian cancer. (Abstract #5023)
  
  *Lana Kandalaft*

• Discussion
  
  *Elise C. Kohn, MD*

• Phase II trial of temsirolimus and bevacizumab for initial recurrence of endometrial cancer. (Abstract #5025)
  
  *Mark H. Einstein*

• Brief family history questionnaire for identification of Lynch syndrome in women with newly diagnosed endometrial cancer. (Abstract #5026)
  
  *Sarah E Ferguson*
• Efficacy and safety of the APE (actinomycin D, cisplatin, etoposide) regimen for the management of high-risk gestational trophoblastic neoplasia. (Abstract #5028)
  Catherine Lhomme
• Discussion
  David Gardner Mutch, M.D.

• A snapshot of potentially personalized care: Molecular diagnostics in gynecologic cancer. (Abstract #5029)
  Elizabeth Sales

• A comprehensive analysis of BRAF and KRAS mutation status in low-grade serous (LGS) and serous borderline (SB) ovarian cancer (OC). (Abstract #5030)
  Rachel Nicole Grisham

• Topotecan plus carboplatin versus standard therapy with paclitaxel plus carboplatin (PC) or gemcitabin plus carboplatin (GC) or carboplatin plus pegylated doxorubicin (PLDC): A randomized phase III trial of the NOGGO-AGO-Germany-AGO Austria and GEICO-GCIG intergroup study (HECTOR). (Abstract #5031)
  Jalid Sehouli

• Application of micro-RNA (miRNA) expression profiles for prognostication in low-risk endometrial carcinoma (LEC). (Abstract #5032)
  Johanne Ingrid Weberpals

• Randomized, phase III study of carboplatin plus paclitaxel for 8 cycles (CP8) versus carboplatin x 8 cycles plus paclitaxel x 4 cycles (C8P4) in advanced ovarian, fallopian, or primary peritoneal carcinoma. (Abstract #5033)
  Aristotelis Bamias

• Use of HE4 and CA125 to predict surgical outcome and for prognostic value for progression-free survival (PFS) and overall survival (OS) in primary epithelial ovarian cancer (EOC) patients (pts). (Abstract #5034)
  Ioana Braicu

• Functional profiling of clear cell ovarian cancer. (Abstract #5035)
  Rowan Miller

• Use of an optimized primary ovarian cancer xenograft model to mimic patient tumor biology and heterogeneity. (Abstract #5036)
  Zachary C. Dobbin

• Discussion
  Daniela Matei, MD
• Co-Chair
  Roland B. Walter, MD, PhD
• Co-Chair
  Alison R. Walker, MD
Brd. 1
• Nilotinib versus imatinib in patients (pts) with newly diagnosed chronic myeloid leukemia in chronic phase (CML-CP): ENESTnd 3-year (yr) follow-up (f/u). (Abstract #6509^)
  Hagop Kantarjian
Brd. 2
• The prognostic significance of early molecular and cytogenetic response for long-term progression-free and overall survival in imatinib-treated chronic myeloid leukemia (CML). (Abstract #6510)
  Rudiger Hehlmann
Brd. 3
• Efficacy and safety of bosutinib (BOS) for Philadelphia chromosome–positive (Ph+) leukemia in older versus younger patients (pts). (Abstract #6511)
  Tim H. Brummendorf
Brd. 4
• BELA trial update: Bosutinib (BOS) versus imatinib (IM) in patients (pts) with newly diagnosed chronic phase chronic myeloid leukemia (CP CML) after 30 months of follow-up. (Abstract #6512)
  Carlo Gambacorti-Passerini
Brd. 5
• Subcutaneous omacetaxine mepesuccinate in patients with chronic phase (CP) or accelerated phase (AP) chronic myeloid leukemia (CML) resistant/intolerant to two or three approved tyrosine-kinase inhibitors (TKIs). (Abstract #6513)
  Franck E. Nicolini
Brd. 6
• Reductions in JAK2V617F allele burden with ruxolitinib treatment in COMFORT-II, a phase III study comparing the safety and efficacy of ruxolitinib to best available therapy (BAT). (Abstract #6514^)
  Alessandro M. Vannucchi
• Discussion
  Neil P. Shah, MD, PhD
Brd. 7
• Combination of the Bruton's tyrosine kinase (BTK) inhibitor PCI-32765 with bendamustine (B)/rituximab (R) (BR) in patients (pts) with relapsed/refractory (R/R) chronic lymphocytic leukemia (CLL): Interim results of a phase Ib/II study. (Abstract #6515^)
  Susan Mary O'Brien
Brd. 8
• Phase II trial of the combination of ofatumumab and lenalidomide in patients with relapsed chronic lymphocytic leukemia (CLL). (Abstract #6516^)
  Lorenzo Falchi
Brd. 9
• Pretreatment prognostic factors associated with outcomes for first-line FCR-based treatments in previously untreated CLL. (Abstract #6517)
  William G. Wierda
• A phase I/II study of the selective phosphatidylinositol 3-kinase-delta (PI3Kδ) inhibitor, GS-1101 (CAL-101), with ofatumumab in patients with previously treated chronic lymphocytic leukemia (CLL). (Abstract #6518^)

Richard R. Furman

• Sensitivity of refractory hairy cell leukemia to BRAF inhibition. (Abstract #6519)

Sascha Dietrich

• A randomized phase II study of sapacitabine in MDS refractory to hypomethylating agents. (Abstract #6520)

Guillermo Garcia-Manero

• Discussion

Kanti Roop Rai, MD

• Use of single polymorphism arrays (SNP-A) to modify prognostic scoring systems for myelodysplastic syndromes. (Abstract #6521)

Manojkumar Bupathi

• Efficacy and tolerability of lenalidomide (LEN) in patients (pts) 75 and older versus those younger than 75 with RBC transfusion-dependent low/int-1-risk MDS and del 5q. (Abstract #6522)

Pierre Fenaux

• Results of a phase II trial of azacitidine (AZA) with or without epoetin beta (EPO) in lower-risk MDS. (Abstract #6523)

Claude Gardin

• Evaluation of the first-in-class antimitochondrial metabolism agent CPI-613 in hematologic malignancies. (Abstract #6524^)

Timothy S. Pardee

• Initial salvage therapy in first relapse AML: A phase IIb study of CPX-351 versus investigator’s choice—A subset analysis by prognostic group. (Abstract #6525)

Stuart Goldberg

• A phase II study of bortezomib added to standard daunorubicin and cytarabine during induction therapy and to intermediate-dose cytarabine (Int-DAC) for consolidation in patients with previously untreated acute myeloid leukemia (AML) age 60-75 years: CALGB study 10502. (Abstract #6526)

Eyal C. Attar

• Stage I findings of a two-stage phase II study to assess the efficacy, safety, and tolerability of barasertib (AZD1152) compared with low-dose cytosine arabinoside (LDAC) in elderly patients (pts) with acute myeloid leukemia (AML). (Abstract #6527)

Giovanni Martinelli
• Effect of fludarabine, cytarabine, filgrastim, and gemtuzumab ozogamicin (FLAG-GO) on relapse-free survival in patients with newly diagnosed core-binding factor acute myelogenous leukemia. (Abstract #6528)
  Gautam Borthakur

• Allogeneic stem cell transplantation for patients over age 65 with acute myelogenous leukemia and myelodysplastic syndrome. (Abstract #6529)
  Henry Jacob Conter

• Discussion
  Jessica K. Altman, MD

• Clinical trial and compassionate use experience with glucarpidase for methotrexate toxicity. (Abstract #6530)
  Brigitte C. Widemann

• BCR-ABL kinase domain mutations and resistance in Ph+ acute lymphoblastic leukemia from the imatinib to the second-generation TKI era. (Abstract #6531)
  Simona Soverini

• Outcomes of patients older than 60 years with acute lymphoblastic leukemia: Survey from the Surveillance, Epidemiology, and End Results (SEER) program. (Abstract #6532)
  Jae Hong Park

• Impact of donor source on allogeneic stem cell transplantation for Philadelphia chromosome-negative acute lymphoblastic leukemia. (Abstract #6533)
  Satoshi Nishiwaki

• Discussion
  Jane Liesveld, MD

Session Title: 2012 Grant Writing Workshop Program: Basic Grant Writing and Grant Writing Skills
Session Type: Extended Education Session
Time: 1:00 PM - 5:00 PM
Location: S103

• Developing Hypothesis and Stating Aims
  Charles M. Rudin, MD, PhD (Co-Chair)

• Mock Study Session Participant and Small Group Discussion Table Leader
  Eric Jay Small, MD (Co-Chair)

• Conquer Cancer Foundation Grants Program
  Jennifer C. King, PhD

• Choosing a Mentor and Obtaining Letters of Support
  Susan Blaney, MD

• Working with a Biostatistician and Mock Study Participant
  Donna S. Neuberg, ScD

• Grant Writing Pearls
  Mary L. Disis, MD

• Mock Study Participant and Small Group Discussion Table Leader
  Kathleen A. Cooney, MD

• Small Group Discussion Table Leader
  Wells A. Messersmith, MD
**Session Title:** Pediatric Oncology Award and Lecture  
**Session Type:** Special Session  
**Time:** 2:45 PM - 4:00 PM  
**Location:** S504  
**Toward the Total Cure of Childhood Acute Lymphoblastic Leukemia with Personalized Therapy**  
*Ching-Hon Pui, MD*

**Session Title:** Around the World in Almost 80 Minutes: Lung Cancer Care and Research  
**Session Type:** Education Session  
**Time:** 2:45 PM - 4:00 PM  
**Location:** E Arie Crown Theater  
- Research and Standard Care: Lung Cancer in Brazil  
  *Gilberto Schwartsmann, MD, PhD (Chair)*  
- Research and Standard Care: Lung Cancer in China  
  *Tony Mok, MD*  
- Research and Standard Care: Lung Cancer in Romania  
  *Tudor-Eliade Ciuleanu, MD*

**Session Title:** Controversies in the Adjuvant Treatment of Breast Cancer  
**Session Type:** Education Session  
**Time:** 2:45 PM - 4:00 PM  
**Location:** E Hall D1  
- Vexing Issues in Antiestrogen Therapy in the Adjuvant Setting: Choice of Agents, Duration of Therapy, and Ovarian Suppression  
  *Stephen R. D. Johnston, MA, MD, PhD (Chair)*  
- Small Aggressive Tumors: Triple-Negative and HER2-Positive  
  *Anthony D. Elias, MD*  
- Optimizing Adjuvant Therapy Decisions for Elderly Patients with Breast Cancer  
  *Hyman Bernard Muss, MD*

**Session Title:** Immunotherapy with the T-Cell Checkpoint Antibodies: Implications for the Practitioner  
**Session Type:** Education Session  
**Time:** 2:45 PM - 4:00 PM  
**Location:** E354a  
- CTLA-4 Blockade and Beyond: Rationale, Development, Clinical Trial Results, and New T-Cell Checkpoint Agents in Development  
  *Mario Sznol, MD (Chair)*  
- Immune-Related Adverse Events: Description and Treatment  
  *Jeffrey S. Weber, MD, PhD*  
- Immune-Related Response Criteria: Description and Use in the Management of CTLA-4 Blocking Antibody-Treated Patients  
  *F. Stephen Hodi, MD*

**Session Title:** Lessons in Mentorship from a Successful Breast Oncologist - Ticketed Session  
**Session Type:** Meet the Professor Session  
**Time:** 2:45 PM - 4:00 PM  
**Location:** E451a  
**Lessons in Mentorship from a Successful Mentor**  
*Gabriel N. Hortobagyi, MD*
**Session Title:** Bringing Cancer Genome Sequencing to Clinical Oncology  
**Session Type:** Extended Education Session  
**Time:** 3:45 PM - 6:00 PM  
**Location:** E353  
- Cancer Genome Sequencing: New Biological and Therapeutic Insights  
  *Levi A. Garraway, MD, PhD*  
- Clinical Cancer Genome Sequencing: Opportunities and Challenges  
  *Matthew Meyerson, MD, PhD (Chair)*  
- A Framework for Clinical Genome Sequencing in Cancer  
  *Arul Chinnaiyan, MD, PhD*

**Session Title:** Cancer in Obese Individuals: Optimal Treatment and Beyond  
**Session Type:** Extended Education Session  
**Time:** 3:45 PM - 6:00 PM  
**Location:** S100bc  
- Overview of the Relationship between Obesity and Cancer  
  *Rachel Ballard-Barbash, MD, MPH*  
- Obesity and Cancer: Biologic Mechanisms  
  *Pamela Jean Goodwin, MD, MSc (Chair)*  
- Evidence Supporting Weight-Based Chemotherapy Dosing in Obese Patients with Cancer  
  *Jennifer J. Griggs, MD, MPH*  
- The New ASCO Guidelines for Chemotherapy Dosing in Obese Patients  
  *Gary H. Lyman, MD, MPH*  
- The Role of Lifestyle Interventions in the Management of Obese Patients with Cancer  
  *Melinda Irwin, PhD, MPH*  
- Practical Approaches to Managing Overweight and Obese Cancer Patients  
  *Jennifer A. Ligibel, MD*

**Session Title:** Career Choices in Oncology: Options in Academia, Private Practice, Industry, and Government  
**Session Type:** Extended Education Session  
**Time:** 3:45 PM - 6:00 PM  
**Location:** S404  
- Moderator  
  *Jill Gilbert, MD (Chair)*  
- Academia  
  *Lillian L. Siu, MD*  
- Academia  
  *C. D. Blanke, MD*  
- Practice  
  *Barbara L. McAneny, MD*  
- Government  
  *Richard Pazdur, MD*  
- Industry  
  *Mace L. Rothenberg, MD*  
- Hybrid: Private Practice/Academia  
  *Fadi S. Braiteh, MD*

**Session Title:** Virally Mediated Oncogenesis  
**Session Type:** Extended Education Session  
**Time:** 3:45 PM - 6:00 PM  
**Location:** E354b
Liver Cancer and Hepatitis
  
  John Groopman, PhD

HPV in Human Cancer

  Carole Fakhry, MD, MPH

New Aspects of the Association between the Epstein-Barr Virus and Cancer: Diagnosis, Monitoring, Treatment, and Prevention

  Richard F. Ambinder, MD, PhD (Chair)

Discovering Viruses That Cause Cancer (Merkel Cell and KS)

  Jürgen C. Becker, MD, PhD

---

**Session Title:** A Fresh Look at Ductal Carcinoma In Situ: Basic Science to Clinical Management
**Session Type:** Education Session
**Time:** 4:30 PM - 5:45 PM
**Location:** E Hall D1

The Premalignant Biology of Ductal Carcinoma In Situ and the Microenvironment

  Victoria Louise Seewaldt, MD

The Incidence and Prevalence of Ductal Carcinoma In Situ and the Influence of the Mode of Detection, Population Characteristics, and Other Risk Factors

  Beth A. Virnig, PhD

Locoregional Therapy Ductal Carcinoma In Situ: How Much Is Enough?

  Eun-Sil Shelley Hwang, MD, MPH (Chair)

---

**Session Title:** Adaptive Clinical Trial Designs: What Are They and Should They Be Used?
**Session Type:** Education Session
**Time:** 4:30 PM - 5:45 PM
**Location:** S504

Introduction to Adaptive Designs

  Mary Weber Redman, PhD (Chair)

Present "Pro" Argument

  J. Jack Lee, PhD, DDS

Present "Con" Argument

  Marc E. Buyse, ScD

---

**Session Title:** Selection Criteria for Universal Screening and Prevention of Lynch Syndrome - Ticketed Session
**Session Type:** Meet the Professor Session
**Time:** 4:30 PM - 5:45 PM
**Location:** E451a

Overview of Screening for Lynch Syndrome

  John Burn, MD

---

**Session Title:** Challenging Questions in the Neoadjuvant Management of Breast Cancer - Ticketed Session
**Session Type:** Clinical Problems in Oncology Session
**Time:** 4:30 PM - 5:45 PM
**Location:** E451b

Challenges in Surgical Management of Patients Receiving Neoadjuvant Therapy

  Emiel J. Rutgers, MD, PhD

How Does Neoadjuvant Chemotherapy Complicate Radiation Decisions?

  Lori J. Pierce, MD

Systemic Challenges with Neoadjuvant Therapy

  Erica L. Mayer, MD, MPH (Chair)